Immunome, Inc. (IMNM)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (60.1M) | (72.9M) | (59.3M) | (78.1M) |
| Net Income | (57.5M) | (69.9M) | (53.8M) | (73.1M) |
| Diluted EPS | $-0.65 | N/A | $-0.48 | $-0.65 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 14.0M | 9.0M | 6.9M |
| Operating Income | (36.9M) | (28.7M) | (153.5M) | (224.1M) |
| Net Income | (36.9M) | (106.8M) | (293.0M) | (212.4M) |
| Diluted EPS | $-3.09 | $-5.38 | $-5.00 | $-2.43 |